Shares of Tatva Chintan Pharma Chem zoomed 17 per cent to Rs 2,488.90 on the BSE in Monday’s intraday trade after the company reported a robust set of numbers for the quarter ended September 2021 (Q2FY22), on back of higher revenue. The stock of the specialty chemicals was trading at its highest level since its listing on July 29, 2021.

• Orient Cables Eyes Rs 3,500 Crore Revenue By FY30
• Bangladesh Resumes Indian Wheat Purchases as Black Sea Disruptions Lift Prices
• Central Railway Recovers Rs 140 Crore In Ticket Fines
• Cosmic CRF Unit Bags Rs 25.94 Crore Combined Orders
• Arivihan in Talks to Raise Rs 96 Crore at Rs 570 Crore Valuation

For Q2FY22, Tatva Chintan’s consolidated net profit jumped over nine-fold to Rs 32.41 crore as against Rs 3.56 crore in Q2FY21. Revenue from operations during the quarter more than doubled to Rs 123.62 crore from Rs 60.04 crore in the corresponding quarter of previous fiscal. The company’s, earnings before interest, tax, depreciation and amortization (ebitda) margin improved to 31.3 per cent from 13.85 per cent.